Macquarie Group Ltd. purchased a new stake in shares of CareDx (NASDAQ:CDNA) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 25,900 shares of the company’s stock, valued at approximately $190,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CDNA. FNY Partners Fund LP purchased a new position in shares of CareDx during the 4th quarter valued at $102,000. Two Sigma Advisers LP purchased a new position in shares of CareDx during the 4th quarter valued at $105,000. Wells Fargo & Company MN grew its position in shares of CareDx by 1,360.6% during the 4th quarter. Wells Fargo & Company MN now owns 16,636 shares of the company’s stock valued at $122,000 after purchasing an additional 15,497 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of CareDx during the 4th quarter valued at $130,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CareDx during the 4th quarter valued at $134,000. Hedge funds and other institutional investors own 51.50% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, insider Peter Maag sold 15,000 shares of the company’s stock in a transaction on Tuesday, March 27th. The shares were sold at an average price of $7.87, for a total value of $118,050.00. Following the completion of the transaction, the insider now directly owns 272,037 shares in the company, valued at $2,140,931.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is currently owned by insiders.

A number of research firms have recently commented on CDNA. HC Wainwright set a $12.00 price target on shares of CareDx and gave the company a “buy” rating in a research report on Friday, March 23rd. TheStreet upgraded shares of CareDx from a “d-” rating to a “c-” rating in a research report on Tuesday, April 10th. ValuEngine upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $8.65.

Shares of NASDAQ:CDNA opened at $8.95 on Tuesday. CareDx has a 52-week low of $0.76 and a 52-week high of $9.29. The firm has a market capitalization of $261.96, a P/E ratio of -11.62 and a beta of 0.35. The company has a quick ratio of 0.50, a current ratio of 0.62 and a debt-to-equity ratio of -3.08.

CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, March 22nd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. CareDx had a negative net margin of 114.79% and a negative return on equity of 349.65%. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $12.09 million. sell-side analysts predict that CareDx will post -0.34 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Macquarie Group Ltd. Invests $190,000 in CareDx (CDNA)” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2018/04/17/macquarie-group-ltd-invests-190000-in-caredx-cdna.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx (NASDAQ:CDNA).

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.